21 February 2020

• NIAID launches a COVID-19 adaptive clinical trial including remdesivir. Source
• Favilavir, a version of favipiravir, produced by Zhejiang Hisun Pharmaceuticals, is approved as an investigational drug for COVID-19 in China, based on data from Shenzhen, Guangdong province. Sources 1,2
• First report of asymptomatic spread of COVID-19. Source

Return to the timeline